N
Niels Smedegaard Andersen
Researcher at Copenhagen University Hospital
Publications - 61
Citations - 2280
Niels Smedegaard Andersen is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Transplantation & Mantle cell lymphoma. The author has an hindex of 17, co-authored 55 publications receiving 1997 citations. Previous affiliations of Niels Smedegaard Andersen include University of Copenhagen.
Papers
More filters
Journal ArticleDOI
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler,Arne Kolstad,Anna Laurell,Niels Smedegaard Andersen,Lone Bredo Pedersen,Mats Jerkeman,Mikael Eriksson,Marie Nordström,Eva Kimby,Anne Marie Boesen,Outi Kuittinen,Grete F. Lauritzsen,Herman Nilsson-Ehle,Elisabeth Ralfkiaer,Måns Åkerman,Mats Ehinger,Christer Sundström,R. Langholm,Jan Delabie,Marja-Liisa Karjalainen-Lindsberg,Peter de Nully Brown,Erkki Elonen +21 more
TL;DR: Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression-free survival of MCL and perhaps cure.
Journal ArticleDOI
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
Christian H. Geisler,Arne Kolstad,Anna Laurell,Mats Jerkeman,Riikka Räty,Niels Smedegaard Andersen,Lone Bredo Pedersen,Mikael Eriksson,Marie Nordström,Eva Kimby,Hans Bentzen,Outi Kuittinen,Grete F. Lauritzsen,Herman Nilsson-Ehle,Elisabeth Ralfkiaer,Mats Ehinger,Christer Sundström,Jan Delabie,Marja-Liisa Karjalainen-Lindsberg,Peter de Nully Brown,Erkki Elonen +20 more
TL;DR: The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event‐free survival of 7·4 years, however, six patients have now progressed later than 5 years after end of treatment.
Journal ArticleDOI
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Christiane Pott,Eva Hoster,Marie-Hélène Delfau-Larue,Kheira Beldjord,Sebastian Böttcher,Vahid Asnafi,Anne Plonquet,Reiner Siebert,Evelyne Callet-Bauchu,Niels Smedegaard Andersen,Jacques J.M. van Dongen,Wolfram Klapper,Françoise Berger,Vincent Ribrag,Achiel Van Hoof,Marek Trneny,Jan Walewski,Peter Dreger,Michael Unterhalt,Wolfgang Hiddemann,Michael Kneba,Hanneke C. Kluin-Nelemans,Olivier Hermine,Elizabeth Macintyre,Martin Dreyling +24 more
TL;DR: The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma treated within 2 randomized trials of the European MCL Network and emerged to be an independent prognostic factor for RD.
Journal ArticleDOI
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Peter Dreger,Johannes Schetelig,Niels Smedegaard Andersen,Paolo Corradini,Michel van Gelder,John G. Gribben,Eva Kimby,Mauricette Michallet,Carol Moreno,Stephan Stilgenbauer,Emili Montserrat +10 more
TL;DR: Until the risks and benefits of different treatment strategies are settled, all patients with high-risk chronic lymphocytic leukemia should be considered for treatment with BCRi/BCL2a, according to currently available evidence and theoretical considerations.
Journal ArticleDOI
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
Christian Winther Eskelund,Arne Kolstad,Mats Jerkeman,Riikka Räty,Anna Laurell,Sandra Eloranta,Karin E. Smedby,Simon Husby,Lone Bredo Pedersen,Niels Smedegaard Andersen,Mikael Eriksson,Eva Kimby,Hans Bentzen,Outi Kuittinen,Grete F. Lauritzsen,Herman Nilsson-Ehle,Elisabeth Ralfkiaer,Mats Ehinger,Christer Sundström,Jan Delabie,Marja-Liisa Karjalainen-Lindsberg,Christopher T. Workman,Christopher T. Workman,Christian Garde,Christian Garde,Erkki Elonen,Peter de Nully Brown,Kirsten Grønbæk,Christian H. Geisler +28 more
TL;DR: Even though the Nordic regimen is considered as a very good choice of regimen, it is recommended inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.